Resproly Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
74
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$7.12M
- Investors
-
14
Resproly General Information
Description
Developer and provider of inhaled formulations and pulmonary drug delivery technology for respiratory disease. The company is mainly focuses on the research and development of treatments for Asthma, COPD (Chronic Obstructive Pulmonary Disease), diabetes, and Parkinson's Disease.
Contact Information
Website
www.resproly.comCorporate Office
- Room 683, Block A, Huameiju Business Center, Xinhu Road, District 82, Haiyu Community
- Xin'an Street, Bao'an District
- Shenzhen, Guangdong 518102
- China
Corporate Office
- Room 683, Block A, Huameiju Business Center, Xinhu Road, District 82, Haiyu Community
- Xin'an Street, Bao'an District
- Shenzhen, Guangdong 518102
- China
Resproly Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 15-Apr-2026 | $7.12M | Completed | Generating Revenue | ||
| 8. IPO | 27-Jun-2025 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC | 30-Apr-2022 | Completed | Clinical Trials - General | |||
| 6. Secondary Transaction - Private | 22-Apr-2022 | Completed | Clinical Trials - General | |||
| 5. Secondary Transaction - Private | 02-Apr-2021 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series B) | 01-Feb-2021 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC | 28-Feb-2020 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 25-Sep-2019 | $7.02M | $11.8M | Completed | Clinical Trials - General | |
| 1. Seed Round | 01-May-2018 | $4.76M | $4.76M | Completed | Startup |
Resproly Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 6,923,077 | $1.12 | $1.12 | 1x | $1.12 | 17.41% |
Resproly Patents
Resproly Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026138739-A1 | Il-4r binding molecule and use thereof | Pending | 26-Dec-2024 | ||
| US-11475798-B2 | Simulation device for characterizing aerodynamics of dry power inhalants in respiratory system | Active | 11-Jun-2019 | ||
| US-20200394937-A1 | Simulation device for characterizing aerodynamics of dry power inhalants in respiratory system | Active | 11-Jun-2019 | ||
| GB-201905668-D0 | A device for measuring tablet and granule dissolution and disintegration | Inactive | 23-Apr-2019 | ||
| GB-2583468-A | A device for measuring tablet and granule dissolution and disintegration | Inactive | 23-Apr-2019 | G01N13/00 |
Resproly Signals
Resproly Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Guangzhou Industrial Investment Holding Group | Government | Minority | ||
| Fuho Capital | Venture Capital | Minority | ||
| CAS Investment Management | Growth/Expansion | Minority | ||
| Cowin Capital | Venture Capital | Minority | ||
| Qianhai FoF | Fund of Funds | Minority |
Resproly FAQs
-
When was Resproly founded?
Resproly was founded in 2018.
-
Where is Resproly headquartered?
Resproly is headquartered in Shenzhen, China.
-
What is the size of Resproly?
Resproly has 74 total employees.
-
What industry is Resproly in?
Resproly’s primary industry is Drug Delivery.
-
Is Resproly a private or public company?
Resproly is a Private company.
-
What is the current valuation of Resproly?
The current valuation of Resproly is .
-
What is Resproly’s current revenue?
The current revenue for Resproly is .
-
How much funding has Resproly raised over time?
Resproly has raised $61.8M.
-
Who are Resproly’s investors?
Guangzhou Industrial Investment Holding Group, Fuho Capital, CAS Investment Management, Cowin Capital, and Qianhai FoF are 5 of 14 investors who have invested in Resproly.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process